Shanghai Wennai Pharmaceutical Technology synthesizes new CYP11A1 inhibitors
July 25, 2024
Shanghai Wennai Pharmaceutical Technology Co. Ltd. has described new cholesterol side-chain cleavage enzyme, mitochondrial (CYP11A1) inhibitors reported to be useful for the treatment of breast and prostate cancer.